Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Drug Patent Watch
NOVEMBER 4, 2023
This chart shows the drugs with the most patents in Morocco. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Morocco? appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
Melpida is under clinical development by Elpida Therapeutics and currently in Phase II for Paraplegia.
Expert insights. Personalized for you.
130 
Let's personalize your content